In the trial, conducted at the Sourasky Medical Center in Tel Aviv, a total of 60 male and female participants, aged 55-75, received two intramuscular injections containing the vaccine, either with or without adjuvant, and at two different dose levels. This was followed by an administration of a commercially available seasonal influenza vaccine.
In this second clinical trial, as in the first (which was conducted with a younger population), the results show that BiondVax's Multimeric-001 Universal Flu Vaccine is safe and well-tolerated at all doses tested, both with and without adjuvant, and that the vaccine successfully activated the two arms of the human immune system - the humoral (antibody) arm and the cellular arm.
In light of the successful conclusion of the two Phase I/II clinical trials, BiondVax is preparing, as planned, to enter into Phase II clinical trials in the second half of 2010. BiondVax will be financing this trial itself." (source)
View More On Medical
